NASDAQ : BNTX
BioNTech SE — Key statistics
Healthcare · Biotechnology · Germany
Last price 87.715 USD (Oct 30, 2026, 2:19 PM EDT) · Market cap 22.03B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 22.15B |
| Enterprise Value | 7.13B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 251.20M |
| Shares Change (YoY) | +3.00% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 16.01% |
| Owned by Institutions (%) | 19.49% |
| Float | 109.28M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.32 |
| Forward PS | 10.79 |
| PB Ratio | 1.09 |
| P/TBV Ratio | 1.21 |
| P/FCF Ratio | 42.31 |
| P/OCF Ratio | 29.21 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 2.35 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 13.62 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.85 |
| Quick Ratio | 7.03 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.69 |
| Interest Coverage | -127.06 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -9.30% |
| Return on Assets (ROA) | -5.41% |
| Return on Invested Capital (ROIC) | -36.69% |
| Return on Capital Employed (ROCE) | -9.88% |
| Weighted Average Cost of Capital (WACC) | 11.02% |
| Revenue Per Employee | $387,797 |
| Profits Per Employee | -$246,785 |
| Employee Count | 7,807 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 3.74 |
Taxes
| Measure | Value |
|---|
| Income Tax | 65.01M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.25 |
| 52-Week Price Change | -14.69% |
| 50-Day Moving Average | 97.24 |
| 200-Day Moving Average | 97.10 |
| Relative Strength Index (RSI) | 40.63 |
| Average Volume (20 Days) | 1,152,697 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.27M |
| Short Previous Month | 2.50M |
| Short % of Shares Out | 3.40% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.35 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 3.03B |
| Gross Profit | 2.32B |
| Operating Income | -2.08B |
| Pretax Income | -1.86B |
| Net Income | -1.93B |
| EBITDA | -1.58B |
| EBIT | -2.08B |
| Loss Per Share | -$7.77 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 15.38B |
| Total Debt | 361.13M |
| Net Cash | 15.02B |
| Net Cash Per Share | $59.80 |
| Equity (Book Value) | 20.29B |
| Book Value Per Share | 80.76 |
| Working Capital | 15.25B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 758.28M |
| Capital Expenditures | -234.84M |
| Depreciation & Amortization | 486.63M |
| Net Borrowing | 25.99M |
| Free Cash Flow | 523.45M |
| FCF Per Share | $2.08 |
Margins
| Measure | Value |
|---|
| Gross Margin | 76.62% |
| Operating Margin | -68.57% |
| Pretax Margin | -61.49% |
| Profit Margin | -63.64% |
| EBITDA Margin | -52.11% |
| EBIT Margin | -68.57% |
| FCF Margin | 17.71% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.00% |
| Shareholder Yield | -3.00% |
| Earnings Yield | -8.82% |
| FCF Yield | 2.36% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $116.72 |
| Price Target Difference | 32.38% |
| Analyst Consensus | Buy |
| Analyst Count | 21 |
| Revenue Growth Forecast (3Y) | -7.47% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 6.71 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |